Skip to main content
. 2018 Nov 14;53(2):75–85. doi: 10.4132/jptm.2018.10.11

Fig. 3.

Fig. 3.

(A) Disease-specific survival (DSS) of all patients with breast cancer based on human leukocyte antigen class I (HLA-I) expression (p=.029). (B) Disease-free survival (DFS) of all patients with breast cancer based on HLA-I expression (p=.863). (C) DSS of the patient subgroup with stage II–IV breast cancer based on HLA-I expression (p=.007). (D) DFS of the patient subgroup with stage II–IV breast cancer based on HLA-I expression (p=.506).